Table 1.
Baseline characteristics of the study sample
| All (n = 258) | Stable MCI (n = 119) | Progressive MCI (n = 139) | p valuec | |
|---|---|---|---|---|
| Age, years | 74.1 (69.5–78.5) | 74.4 (69.1–78.2) | 73.6 (69.8–78.7) | > 0.999 |
| Female, n (%) | 101 (39.1) | 40 (33.6) | 61 (43.9) | 0.119 |
| Education, years | 16 (14–18) | 16 (14–18) | 16 (14–18) | 0.469 |
| APOE ε4 carrier, n (%) | 176 (68.2) | 78 (65.6) | 98 (70.5) | 0.473 |
| Cognition | ||||
| MMSE | 27 (25–29) | 28 (26–29) | 26 (25–28) | < 0.001 |
| CDR SB | 1.5 (1.0–2.5) | 1.5 (1.0–2.0) | 2.0 (1.0–2.5) | < 0.001 |
| ADAS-cog 11 | 11.8 (9.0–15.7) | 10.7 (7.2–13.2) | 13.0 (10.8–16.2) | < 0.001 |
| CSF markers | ||||
| Aβ1–42, mean ± SD, pg/mL | 136.1 ± 25.7 | 136.7 ± 27.2 | 133.7 ± 25.0 | 0.345 |
| CSF t-tau, pg/mLa | 104.0 (77.0–148.5) | 91.0 (68.0–133.0) | 113.0 (84.0–153.0) | 0.006 |
| CSF p-tau, pg/mLb | 41.0 (31.0–58.0) | 37.0 (27.0–51.0) | 45.0 (36.0–64.0) | < 0.001 |
| MRI | ||||
| Tesla, n (%) | 0.714 | |||
| 1.5 | 143 (55.4) | 64 (53.8) | 79 (56.8) | |
| 3.0 | 115 (44.6) | 55 (46.2) | 60 (43.2) | |
| MTA, n (%) | 123 (47.7) | 47 (39.5) | 76 (54.7) | 0.021 |
| PA, n (%) | 174 (67.4) | 65 (54.6) | 109 (78.4) | <0.001 |
| Atrophy pattern, n (%) | <0.001 | |||
| No atrophy | 51 (19.8) | 39 (32.8) | 12 (8.6) | |
| MTA only | 33 (12.8) | 15 (12.6) | 18 (13.0) | |
| PA only | 84 (32.6) | 33 (27.7) | 51 (36.7) | |
| Both MTA and PA | 90 (34.9) | 32 (26.9) | 58 (41.7) | |
Data are presented as the median (interquartile range) unless otherwise specified
a Data for 7 subjects were not available
b Data for 1 subject were not available
c Stable MCI vs. progressive MCI
Aβ β-amyloid, ADAS-cog Alzheimer’s Disease Assessment Scale-cognitive subscale, CDR SB Clinical Dementia Rating Sum of Boxes, CSF cerebrospinal fluid, MCI mild cognitive impairment, MMSE Mini-Mental State Examination, MRI magnetic resonance imaging, MTA medial temporal lobe atrophy, PA posterior atrophy, p-tau tau phosphorylated at threonine 181, SD standard deviation, t-tau total tau